Compound: Peramivir
SMILES: O=C(O)[C@@H]1[C@@H](O)[C@@H]([C@@H](NC(=O)C)C(CC)CC)[C@@H](C1)NC(=N)N
InChIKey: XRQDFNLINLXZLB-CKIKVBCHSA-N
Synonyms: Peramivir, 330600-85-6, BCX-1812, Rapiacta, RWJ-270201, Peramivir anhydrous, RAPIVAB, BCX 1812, BCX1812, 9ZS94HQO3B, RWJ270201, RWJ 270201, CHEBI:85202, RWJ-270201-162 ANHYDROUS, DTXSID10904727, 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid, Cyclopentanecarboxylic acid, 3-((1S)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1S,2S,3R,4R)-, Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)-, PERAMIVIRUM, RefChem:860138, J05AH03, DTXCID801333836, (1S,2S,3R,4R)-3-((1S)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino-2-hydroxycyclopentanecarboxylic acid, trihydrate, 1N-(1-(5-diaminomethylamino-3-dihydroxymethyl-2-hydroxy-(3S,5R)-cyclopentyl)-2-ethylbutyl)acetamide (BCX-1812), (1S,2S,3R,4R)-3-((1S)-1-acetamido-2-ethylbutyl)-4-((amino(imino)methyl)amino)-2-hydroxycyclopentanecarboxylic acid trihydrate, QW7Y7ZR15U, 229614-55-5, (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid, Peramivir, (+/-)-, (1S,2S,3R,4R)-3-((S)-1-Acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid, 229614-56-6, (1S,2R,3R,4R)-3-(1-acetamido-2-ethyl-butyl)-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid, (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid, IDL9Q29886, (1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxycyclopentanecarboxylic Acid, 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID, BCZ, (1S,2S,3S,4R)-4-[(DIAMINOMETHYLIDENE)AMINO]-3-[(1S)-1-ACETAMIDO-2-ETHYLBUTYL]-2-HYDROXYCYCLOPENTANE-1-CARBOXYLIC ACID, (+/-)-Peramivir, Peramivir [USAN:INN], UNII-9ZS94HQO3B, PeramiFlu, UNII-IDL9Q29886, RWJ-270201;BCX-1812, MFCD09837902, 330600-85-6 (free), PERAMIVIR [INN], PERAMIVIR [MI], Peramivir Impurity 123, orb134426, SCHEMBL744373, BDBM5024, CHEMBL139367, orb1705122, SCHEMBL12795462, GLXC-05004, BDBM50181441, EBC-26603, HY-17015A, AKOS016007760, AKOS037652424, PERAMIVIR (+/-)-FORM [MI], CS-0638, DB06614, DT-0029, FP65126, NCGC00346433-06, NCGC00346433-07, (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane, (1S,2S,3R,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentane-1-carboxylic acid, AC-22715, Cyclopentanecarboxylic acid, 3-((1R)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1R,2R,3S,4S)-rel-, NS00069710, P2892, W19713, AB01566838_01, EN300-7412041, Q412734, S-021812, BRD-K00519864-341-02-5, BRD-K00519864-341-03-3, (-)-(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic Acid, (1S,2S,3R,4R)-3-((1S)-1-ACETYLAMINO-2-ETHYLBUTYL)-4-((AMINOIMINOMETHYL)AMINO)-2-HYDROXYCYCLOPENTANECARBOXYLIC ACID, (1S,2S,3R,4R)-3-(1-acetaMido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid, (1S,2S,3R,4R)-3-[(1S)-1-(ACETYLAMINO)-2-ETHYLBUTYL]-4-{[AMINO(IMINO)METHYL]AMINO}-2-HYDROXYCYCLOPENTANE-1-CARBOXYLIC ACID, (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic acid, (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid, (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid, (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid, (1S,2S,3S,4R)-3-[(1S)-1-Acetamido-2-ethylbutyl]-4-[(diaminomethylidene)amino]-2-hydroxycyclopentane-1-carboxylic acid, CYCLOPENTANECARBOXYLIC ACID, 3-((1S)-1-(ACETYLAMINO)-2-ETHYLBUTYL)-4-((AMINOIMINOMETHYL)AMINO)-2-HYDROXY-, (1R,2R,3S,4S)-REL-
Theoretical properties:
molecular_formula: C15H28N4O4
molecular_weight: 328.41 g/mol
exact_mass: 328.21105539 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 5
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 7
heavy_atom_count: 23
topological_polar_surface_area: 151 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Peramivir is a member of the class of guanidines that is used (as its trihydrate) for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. It has a role as an antiviral drug and an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor. It is a member of acetamides, a member of cyclopentanols, a member of guanidines and a 3-hydroxy monocarboxylic acid. It contains a peramivir hydrate.
chebi: A member of the class of guanidines that is used (as its trihydrate) for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.
chembl: PERAMIVIR ANHYDROUS is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Peramivir (trade name Rapivab) is an antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration.
In October 2009, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the use of peramivir based on safety data from phase I, phase II, and limited phase III trial data. The emergency use authorization for peramivir expired in June 2010. On 19 December 2014, the FDA approved peramivir to treat influenza infection in adults.